{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122230","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.698571+00:00","generated_at":"2026-05-30T04:30:32.972411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M","bullets":["Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).","Net loss $39.1M includes $26.0M non-cash warrant expense; cash $143.7M.","Raised FY2024 revenue guidance to $83-84M from $79-81M; Q4 revenue expected $15-16M.","Delivered 945 molecular tests in Q3, a 68% sequential increase.","Raised ~$62.2M net from Tempus warrant exercise and ATM stock sales."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122230","json":"https://secwatch.observer/filing/0000950170-24-122230.json","markdown":"https://secwatch.observer/filing/0000950170-24-122230.md","text":"https://secwatch.observer/filing/0000950170-24-122230.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024122230/0000950170-24-122230-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024122230/psnl-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:30:32.972411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}